Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marpai, Inc. filings document material events, capital-structure matters and operating disclosures for a healthcare technology company whose Class A common stock trades on the OTCQX Market under MRAI. Recent Form 8-K reports cover results of operations, material definitive agreements and governance matters.
The filing record includes disclosures on promissory-note financing for working capital, amendments to note terms, officer appointments, and charter changes authorizing blank-check preferred stock. Marpai filings also identify its registered Class A common stock, emerging growth company status in certain reports, and formal risk and compliance references tied to its public-company reporting obligations.
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.